HomeBUSINESS
BUSINESS

Sanofi to Focus on Increasing Prescriptions of Lantus XR Based on Results of Head-to-Head Comparison Study
(Sep.10.2018)

Since data from a clinical trial showed a lower rate of hypoglycemic events with Lantus XR Injection SoloStar (insulin glargine) compared to insulin degludec during the first 12 weeks after starting insulin therapy, Sanofi will focus on increasing prescriptions of the product in patients with type 2 diabetes who had not previously started insulin therapy ...
(LOG IN FOR FULL STORY)

News Calendar